Dechra Pharmaceuticals PLC
DCHPF
Other OTC46.90
USD
-0.10
- -
Dechra Pharmaceuticals PLC
DCHPF
(Other OTC)
Recent
price
46.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Dechra Pharmaceuticals PLC operates as a global specialist veterinary pharmaceuticals and related products company, focusing on the development, manufacture, marketing and sales of high-quality medications and therapies exclusively for veterinarians worldwide; its core portfolio spans companion animal products in endocrinology such as Vetoryl and Zycortal for adrenal conditions, topical dermatology treatments, analgesia, anaesthetics and pain management solutions, equine lameness therapies, nutrition products including Phycox, differentiated generics, and additional offerings like water-soluble antibiotics, poultry vaccines and pain management for poultry, pigs and cattle. The company distributes directly into approximately 25 countries through a technical salesforce of qualified veterinarians and reaches over 60 additional markets via wholesalers and distributors, targeting primarily companion animals (CAP) alongside livestock segments in regions including Europe, North America and beyond. Founded in 1997 and headquartered at 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, UK, Dechra emphasizes niche therapeutic areas like endocrinology, dermatology, anaesthesia, pain and inflammation to address unmet needs and support animal health and welfare. In recent developments, Dechra was taken private in January 2024 by an EQT-led consortium in one of the largest UK healthcare sponsor-backed transactions, following its delisting from the London Stock Exchange after trading publicly since 2001; it announced the acquisition of Invetx in July 2024 for up to $520 million to bolster its pipeline with species-specific monoclonal antibodies for chronic companion animal conditions like atopic dermatitis and osteoarthritis, enhancing innovation in protein-based therapeutics.